Introducing the 3rd international Psychiatry and Addiction Masterclass (3rd iPAM®)
Chair: Dr Shahid Latif
This presentation captures real-world experience from the NHS in implementing Ketamine treatment for Treatment-Resistant Depression. Sharing treatment protocols, it highlights how a motivated team, working within the constraints of limited resources, established and sustains an innovative service that is making a positive difference in clinical outcomes.
Dr Louise Sell, Consultant Psychiatrist, Pennine Care NHS Foundation Trust (Confirmed)
There is new evidence to suggest that the co-occuren of autism and ADHD can be as much as 50-70%. In the colloquial community, this co occurrence is temed as AuDHD, is this a new term or a New Diagnosis on the horizon or an extension of the spectrum … The presentation of co-occuring Autism and ADHD is different from that of Pure Autism or Pure ADHD and are there different types of AuDHD … this will all be covered in this session…
As clinicians, we are increasingly recognising and developing competencies in identifying and managing neurodiversity-related conditions, particluarly adult ADHD and autism. Individuals with a dual diagnosis—neurodiversity co- occurring with other mental health conditions such as addictions—pose a distinct set of clinical challenges. Their addictive behaviours, whether substance-related or behavioural (e.g. problem gambling, gaming, internet use, social media, or smartphone overuse), may present atypically and often prove more resistant to conventional treatment approaches.
This presentation explores the complexities of such dual diagnosis cases, with a focus on both substance misuse and the growing recognition of behavioural addictions. It underscores the need for mental health services to adapt and provide responsive, neurodiversity-informed care pathways.
Speaker:
Prof Henrietta Bowden-Jones
The Royal College of Psychiatrists is a global organisation through its international membership. This global reach brings responsibilities in raising standards in mental health across the world. However, there are challenges in working internationally which need addressing. The International Strategy of the Royal College of Psychiatrists provide a framework for working effectively with members and partners to meet those challenges.
Long-Acting Injectable Buprenorphine is a recent advance in the treatment of opioid use disorder which can be administered in weekly or monthly injections, allowing people with opioid use disorder to engage with daily activities without the need or daily supervised consumption. However, there is little research on the how and why this treatment may be beneficial compared to standard of care.
This talk discusses a study where we compared self-reported outcomes for people who are prescribed Long-Acting Injectable Buprenorphine compared to other medications for opioid use disorder. We used logistic regression to identify predictors of being prescribed LAIB compared to other medication for opioid use disorder, and we compared changes in self-reported physical health, mental health and quality of life over a one-year period. We contextualised the results with qualitative interviews with people with opioid use disorder and clinicians.
Closing remarks for the 3rd iPAM
